Treace Medical Concepts (TMCI) to Release Quarterly Earnings on Thursday

Treace Medical Concepts (NASDAQ:TMCI) is anticipated to announce its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect Treace Medical Concepts to post earnings of ($0.15) per share and revenue of $61.7630 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 27, 2026 at 8:00 AM ET.

Treace Medical Concepts Price Performance

Shares of TMCI opened at $1.85 on Thursday. The business’s 50-day moving average is $2.45 and its 200-day moving average is $4.60. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.37 and a quick ratio of 2.36. The company has a market capitalization of $117.88 million, a price-to-earnings ratio of -2.31 and a beta of 0.74. Treace Medical Concepts has a fifty-two week low of $1.81 and a fifty-two week high of $10.30.

Institutional Investors Weigh In On Treace Medical Concepts

A number of large investors have recently added to or reduced their stakes in the stock. Graham Capital Management L.P. bought a new position in shares of Treace Medical Concepts in the fourth quarter valued at approximately $27,000. Osaic Holdings Inc. raised its holdings in Treace Medical Concepts by 328.3% in the 2nd quarter. Osaic Holdings Inc. now owns 4,793 shares of the company’s stock worth $28,000 after acquiring an additional 3,674 shares during the period. HighTower Advisors LLC acquired a new position in Treace Medical Concepts during the 4th quarter worth $33,000. Kestra Advisory Services LLC bought a new stake in Treace Medical Concepts during the fourth quarter valued at about $48,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Treace Medical Concepts in the fourth quarter valued at about $54,000. Institutional investors own 84.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Truist Financial decreased their target price on shares of Treace Medical Concepts from $4.00 to $3.00 and set a “hold” rating for the company in a research note on Thursday, December 18th. Wall Street Zen lowered Treace Medical Concepts from a “hold” rating to a “sell” rating in a report on Sunday. JPMorgan Chase & Co. reaffirmed an “underweight” rating and set a $5.00 price target (down from $8.00) on shares of Treace Medical Concepts in a research note on Friday, November 7th. UBS Group reduced their price target on Treace Medical Concepts from $6.50 to $5.85 and set a “neutral” rating for the company in a report on Friday, November 7th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Treace Medical Concepts in a research note on Wednesday, January 21st. Four analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $4.21.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.